和黄医药(00013)今日盘中大涨5.06%,引起了投资者的广泛关注。根据报道,这主要是因为公司与阿斯利康联合开发的创新药物"沃瑞沙"获得国家药监局批准,用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌。
分析人士指出,这一获批意味着公司的创新药物管线再添新力军,将进一步提升公司业绩增长和市场地位。与此同时,公司还计划加速其抗体靶向偶联药物(ATTC)平台的全球开发,预计2025年下半年启动临床试验。
投资者对公司未来发展前景抱有信心,看好公司的长期增长潜力。据报道,和黄医药还在加快推进其他在研新药的上市进程,不断丰富产品线。整体来看,今日大涨反映了市场对公司创新实力和发展前景的高度认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.